


Product Name : TBI-223
Cat. No. : PC-20073
CAS No. : 2071265-08-0
Molecular Formula : C₁₇H₂₀FN₃O₅
Molecular Weight : 365.36
Target : Bacterial
Solubility : 10 mM in DMSO



Biological Activity

TBI-223 is an oxazolidinone with excellent oral bioavailability and activity against Gram-positive bacteria, works as **protein synthesis** inhibitor, targets an early step involving the binding of N-formylmethionyl-tRNA to the ribosome.

TBI-223 showed reduced human and mouse bone marrow progenitor cell toxicity in vitro and bone marrow toxicity in rat and dog models in vivo, compared to linezolid.

TBI-223 had broader efficacy against other antibiotic-resistant Gram-positive bacteria, including vancomycin-resistant enterococci, penicillin- and ceftriaxone-resistant *Streptococcus pneumoniae*, and coagulase-negative staphylococci. TBI-223 had activity in vitro and in vivo against other bacteria, such as drug-sensitive and drug-resistant *Mycobacterium tuberculosis*.

TBI-223 had significant efficacy against MRSA infections, including in bacteremia, nondiabetic and diabetic skin wound infections, and OIAI.

TBI-223 had efficacy comparable to that of linezolid in all of the mouse models of bacteremia, nondiabetic and diabetic skin wound models, and OIAI.

References

Gordon O, et al. *Microbiol Spectr*. 2022 Oct 26;10(5):e0245121.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com